Skip Nav Destination
Issues
1 July 2021
-
Cover Image
Cover Image
Together with the rest of the cancer research community, Cancer Discovery mourns the untimely death of José Baselga, founding co–Editor-in-Chief of the journal and a luminary in clinical and translational oncology. The Editors-in-Chief have chosen to honor him on this month's journal cover (portrait by Nicolle Fuller of SayoStudio). Read the obituary by Scientific Editors Josep Tabernero, David M. Hyman, and Jean-Charles Soria on page 1614. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 2159-8274
EISSN 2159-8290
Issue Sections
In This Issue
Obituary
In the Spotlight
Mini Reviews
Review
Research Brief
Research Articles
Author Choice
Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer
Francois Gonzalvez; Sylvie Vincent; Theresa E. Baker; Alexandra E. Gould; Shuai Li; Scott D. Wardwell; Sara Nadworny; Yaoyu Ning; Sen Zhang; Wei-Sheng Huang; Yongbo Hu; Feng Li; Matthew T. Greenfield; Stephan G. Zech; Biplab Das; Narayana I. Narasimhan; Tim Clackson; David Dalgarno; William C. Shakespeare; Michael Fitzgerald; Johara Chouitar; Robert J. Griffin; Shengwu Liu; Kwok-kin Wong; Xiaotian Zhu; Victor M. Rivera
Author Choice
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial
Gregory J. Riely; Joel W. Neal; D. Ross Camidge; Alexander I. Spira; Zofia Piotrowska; Daniel B. Costa; Anne S. Tsao; Jyoti D. Patel; Shirish M. Gadgeel; Lyudmila Bazhenova; Viola W. Zhu; Howard L. West; Tarek Mekhail; Ryan D. Gentzler; Danny Nguyen; Sylvie Vincent; Steven Zhang; Jianchang Lin; Veronica Bunn; Shu Jin; Shuanglian Li; Pasi A. Jänne
In a phase I/II clinical trial, mobocertinib—which selectively inhibits EGFR with oncogenic exon 20 insertions—produced objective responses in 43% of previously treated patients with non–small cell lung cancer harboring these mutations.
Author Choice
A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy
Miguel F. Sanmamed; Xinxin Nie; Shruti S. Desai; Franz Villaroel-Espindola; Ti Badri; Dejian Zhao; Anthony W. Kim; Lan Ji; Tianxiang Zhang; Edward Quinlan; Xiaoxiao Cheng; Xue Han; Matthew D. Vesely; Ala F. Nassar; Jingwei Sun; Yu Zhang; Tae Kon Kim; Jun Wang; Ignacio Melero; Roy S. Herbst; Kurt A. Schalper; Lieping Chen
Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling
Christos Adamopoulos; Tamer A. Ahmed; Maxwell R. Tucker; Peter M.U. Ung; Min Xiao; Zoi Karoulia; Angelo Amabile; Xuewei Wu; Stuart A. Aaronson; Celina Ang; Vito W. Rebecca; Brian D. Brown; Avner Schlessinger; Meenhard Herlyn; Qi Wang; David E. Shaw; Poulikos I. Poulikakos
Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo
Giorgia Foggetti; Chuan Li; Hongchen Cai; Jessica A. Hellyer; Wen-Yang Lin; Deborah Ayeni; Katherine Hastings; Jungmin Choi; Anna Wurtz; Laura Andrejka; Dylan G. Maghini; Nicholas Rashleigh; Stellar Levy; Robert Homer; Scott N. Gettinger; Maximilian Diehn; Heather A. Wakelee; Dmitri A. Petrov; Monte M. Winslow; Katerina Politi
A Functional Taxonomy of Tumor Suppression in Oncogenic KRAS–Driven Lung Cancer
Hongchen Cai; Su Kit Chew; Chuan Li; Min K. Tsai; Laura Andrejka; Christopher W. Murray; Nicholas W. Hughes; Emily G. Shuldiner; Emily L. Ashkin; Rui Tang; King L. Hung; Leo C. Chen; Shi Ya C. Lee; Maryam Yousefi; Wen-Yang Lin; Christian A. Kunder; Le Cong; Christopher D. McFarland; Dmitri A. Petrov; Charles Swanton; Monte M. Winslow
PTHrP Drives Pancreatic Cancer Growth and Metastasis and Reveals a New Therapeutic Vulnerability
Jason R. Pitarresi; Robert J. Norgard; Anna M. Chiarella; Kensuke Suzuki; Basil Bakir; Varun Sahu; Jinyang Li; Jun Zhao; Benoît Marchand; Maximilian D. Wengyn; Antony Hsieh; Il-Kyu Kim; Amy Zhang; Karine Sellin; Vivian Lee; Shigetsugu Takano; Yoji Miyahara; Masayuki Ohtsuka; Anirban Maitra; Faiyaz Notta; Richard Kremer; Ben Z. Stanger; Anil K. Rustgi
Bacterial-Driven Inflammation and Mutant BRAF Expression Combine to Promote Murine Colon Tumorigenesis That Is Sensitive to Immune Checkpoint Therapy
Christina E. DeStefano Shields; James R. White; Liam Chung; Alyssa Wenzel; Jessica L. Hicks; Ada J. Tam; June L. Chan; Christine M. Dejea; Hongni Fan; John Michel; Ashley R. Maiuri; Shruthi Sriramkumar; Ram Podicheti; Douglas B. Rusch; Hao Wang; Angelo M. De Marzo; Sepideh Besharati; Robert A. Anders; Stephen B. Baylin; Heather M. O'Hagan; Franck Housseau; Cynthia L. Sears
Loss of Optineurin Drives Cancer Immune Evasion via Palmitoylation-Dependent IFNGR1 Lysosomal Sorting and Degradation
Wan Du; Fang Hua; Xiong Li; Jian Zhang; Shasha Li; Weichao Wang; Jiajia Zhou; Weimin Wang; Peng Liao; Yijian Yan; Gaopeng Li; Shuang Wei; Sara Grove; Linda Vatan; Witold Zgodziński; Marek Majewski; Grzegorz Wallner; Haoyan Chen; Ilona Kryczek; Jing-Yuan Fang; Weiping Zou
CD4 T Cell–Dependent Rejection of Beta-2 Microglobulin Null Mismatch Repair–Deficient Tumors
Giovanni Germano; Steve Lu; Giuseppe Rospo; Simona Lamba; Benoit Rousseau; Sonia Fanelli; Denise Stenech; Dung T. Le; John Hays; Maria Grazia Totaro; Vito Amodio; Rosaria Chilà; Anna Mondino; Luis A. Diaz, Jr.; Federica Di Nicolantonio; Alberto Bardelli
News in Brief
News in Depth
Research Watch
Structural Biology
Clinical Trials
DNA Damage
Sarcoma
Metastasis
Resistance
Immunology
Leukemia
Epigenetics
Genetics
Lung Cancer
Kidney Cancer
Glioma
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds